SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20969)5/17/1998 8:41:00 AM
From: kha vu  Read Replies (1) | Respond to of 32384
 
Hi Henry,
Barron this week (May 16,1998) has an article in which an analyst
reviewing: ENMD, LGND and Agouron. He said that ENMD should be priced
around $18 and LGND will submit NDA around the end of this summer.
Check it out this good article on LGND.



To: Henry Niman who wrote (20969)5/17/1998 10:12:00 AM
From: celeryroot.com  Read Replies (1) | Respond to of 32384
 
Henry, the conversion is .036



To: Henry Niman who wrote (20969)5/17/1998 11:04:00 AM
From: Machaon  Respond to of 32384
 
From the Boston Globe story:

<< However, unlike estrogen, raloxifene did not raise women's HDL
cholesterol - a ''good cholesterol'' that protects against heart disease. >>

There's aways a trade off. I guess, though, that a reduced chance of uterine cancer significantly compensates for the lower levels of HDL.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News